Vitruvias Therapeutics recalls 30 mg thyroid tablets over superpotency

Vitruvias Therapeutics Inc. announced a voluntary recall of one lot of its Thyroid Tablets, USP 30 mg after testing confirmed the product could be superpotent, meaning stronger than labeled.

The recall covers lot number 504950, which carries an expiration date of Sept. 30, 2026, and was distributed nationwide from Jan. 31, 2025 to Sept. 30, 2025, according to the company. Of the 3,655 units released, 1,955 were sold.

Consuming superpotent thyroid tablets can cause hyperthyroidism, or an overactive thyroid, with symptoms including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, and heart rhythm disturbances, the company said. Elderly patients, pregnant women, and infants face the greatest risks, particularly over extended periods. Vitruvias Therapeutics said it has not received any reports of adverse events linked to the recall.

The tablets are a natural preparation derived from porcine thyroid glands and are used to treat hypothyroidism, or an underactive thyroid, the company said. The recalled product can be identified using lot number 504950 or the National Drug Code number 69680-166-00.

Patients currently taking tablets from lot 504950 should not stop taking them without first consulting a healthcare provider for guidance or a replacement prescription, the company said. Vitruvias Therapeutics is notifying wholesalers to halt distribution and arranging for destruction of remaining recalled inventory.

Consumers with questions can reach Vitruvias Therapeutics at safety@vitruvias.com or by phone at (256) 239-9373, Monday through Friday from 9 a.m. to 5 p.m. CT.

This recall follows a separate thyroid medication recall earlier this year. Major Pharmaceuticals initiated a voluntary recall of its levothyroxine sodium tablets in July after the FDA determined those pills were subpotent — delivering less medication than labeled. That recall covered 12 package configurations across multiple dosage strengths and received a Class II designation from the FDA, indicating a potential for temporary negative health effects.